Oral delivery of GLP-1 peptide using recombinant Lactobacillus gasseri for the treatment of type 2 diabetes mellitus
Microbiology Spectrum · 05.08.2025 · 13 (8)
DOI: 10.1128/spectrum.02828-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 05.08.2025. Verfasst von Zhiqiang Ke und 6 weiteren Autor:innen. Beteiligte Einrichtung: Protein Engineering and Biopharmaceuticals science, Hubei University of Technology, Wuhan, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Lactobacillus gasseri. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hubei Provincial Adminstration of Chinese Medicine.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Glucagon-like peptide-1 (GLP-1) is an effective therapeutic peptide for the treatment of type 2 diabetes mellitus (T2DM). Here, we constructed an effective probiotic-based oral GLP-1 delivery system by engineering the probiotic strain of Lactobacillus gasseri ( Lgs GPA ) to secrete GLP-1 fusion peptide, which combines GLP-1 with protein transduction domain (PTD) and a serum albumin binding peptide (ABP), GLP-1-PTD-ABP (GPA). The supernatants of Lgs GPA cultures significantly upregulated the expression of PDX-1 and stimulated insulin release in Min6 cells. Daily oral administration of Lgs GPA in db/db mice significantly alleviated insulin resistance, hyperglycemia, and dyslipidemia. Simultaneously, the abundance of unclassified_f_Erysipelotrichaceae and Intestinimonas was significantly reduced in db/db mice, while the average abundance of Akkermansia increased in the SD rats. These findings demonstrate that the probiotic-based delivery system represents a versatile and effective strategy for the oral administration of therapeutic peptides. Collectively, our results highlight the potential of this probiotic-based approach as a promising therapeutic and preventive intervention for T2DM. IMPORTANCE It is important to develop the oral delivery strategy for therapeutic peptides. Due to issues with patient adherence and the low oral bioavailability of current administration methods, researchers have been exploring oral delivery strategies for GLP-1 analogs for many years, including the use of advanced microbiome therapeutics (AMTs). AMTs offer the potential to use engineered microbes for innovative therapeutic applications, such as the oral delivery of GLP-1 analogs. Our approaches offer a general oral delivery strategy for therapeutic peptides. The probiotic-based approach represents a promising method for treating and preventing T2DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Protein Engineering and Biopharmaceuticals science, Hubei University of Technology, Wuhan, China.
- Institute of Materia Medica, School of Pharmaceutical Sciences, Xinjiang University, Urumqi, China.
- National Demonstration Center for Experimental General Medicine Education, School of Basic Medical Sciences, Hubei University of Science and Technology, Xianning, China.
- Wuhan Biodevelop Inc., Wuhan, China.
ORCID-Profile: Zhiqiang Ke, Xinyuan Zhao, Zhengding Su
Förderung
- Hubei Provincial Adminstration of Chinese Medicine
Zitieren
APA
Ke, Z., Ma, Q., Ye, X., Jin, Y., Wang, Y., Zhao, X., & Su, Z. (2025). Oral delivery of GLP-1 peptide using recombinant Lactobacillus gasseri for the treatment of type 2 diabetes mellitus. Microbiology Spectrum, 13(8). https://doi.org/10.1128/spectrum.02828-24
Vancouver
Ke Z, Ma Q, Ye X, Jin Y, Wang Y, Zhao X, et al. Oral delivery of GLP-1 peptide using recombinant Lactobacillus gasseri for the treatment of type 2 diabetes mellitus. Microbiology Spectrum. 2025;13(8). doi:10.1128/spectrum.02828-24
BibTeX
@article{Ke2025,
author = {Ke, Zhiqiang and Ma, Qianqian and Ye, Xiaonan and Jin, Yan and Wang, Yanlin and Zhao, Xinyuan and Su, Zhengding},
title = {Oral delivery of GLP-1 peptide using recombinant Lactobacillus gasseri for the treatment of type 2 diabetes mellitus},
journal = {Microbiology Spectrum},
year = {2025},
volume = {13},
number = {8},
doi = {10.1128/spectrum.02828-24}
}
EUVIMED